Home Home Our Science+Pipeline News About Foreign cooperation Join Us

Technology

  • Technology Ⅰ

    Pluripotent stem cells were obtained by reprogramming

    Rapid and efficient reprogramming of somatic cells into pluripotent stem cells

  • Technology II

    Gene editing platform

    Efficient establishment of genetically modified pluripotent cell lines

  • Technology III

    Pluripotent stem cell induction and differentiation platform

    Rapid and efficient differentiation of induced human pluripotent stem cells into subtype neurons (glia cell subtype and other functional cell types)

  • Technology IV

    Construction of animal disease models

    Stably established animal models of neurodegenerative diseases

New Drug Pipeline

R&D Collaborative

At present, XellSmart is establishing an industry-university-research cooperation model with enterprises as the main body and relying on top well-known universities and scientific research institutes, so as to provide a strong technical resource guarantee for the development of enterprises. At the same time, XellSmart welcomes interested hospitals, enterprises, and scientific research institutions to contact with our company. By strengthening R&D cooperation, we can build data and scienfitic research platform, actively carry out drug research and development, and realize the integration of cell drug development, clinical research, and clinical transformation of cell products.

Clinical Trials

"Based on its unique technology and R&D platform advantages, Sze is committed to providing large-scale, low-cost stem cell treatment solutions for a series of major Degenerative disease such as Parkinson's disease, which have no clinical solutions. Functional cell types are prepared by inducing and differentiating human pluripotent stem cells in vitro, which are used for cell transplantation to replace Sex therapy means of cell replacement for functional damage or degradation in human body to solve major human diseases. At present, the needle has been launched Pharmaceutical research and preclinical trials for different indications will be conducted, and registration of clinical trials will be initiated as soon as possible Change to "Based on its unique technology and R&D platform advantages, Sze is committed to providing large-scale, low-cost stem cells and immunotherapy solutions for a series of major Degenerative disease or solid tumors such as Parkinson's disease, which have no clinical solutions. It produces functional cell types by inducing and differentiating human pluripotent stem cells in vitro, which is used to replace cells damaged or degraded in human body with cell transplantation to solve major human diseases Or immune cell therapy for tumor diseases. Currently, pharmaceutical research and clinical trials targeting different indications have been conducted, and it is expected to enter the registered clinical trial phase in 2024